Grant History
- October 2024 - $1M
- December 2024 - $2M
- September 2025 - $1M
- December 2025 - $1.1M
This $5.1M of total grant support we've given to funding research is made possible by the generosity of our sponsors and donors. Real people making an impact on saving children's eyesight.
Latest Posts
First Patients Treated in jCell RP Trial
jCyte has launched its Phase 2 JC02-88 trial testing jCell, a potential regenerative therapy for retinitis pigmentosa. This study could bring the first treatment option to the majority of RP patients, offering hope across all genetic subtypes.
FDA Fast Tracks Potential RP Treatment
Aldeyra’s ADX-2191 has received Fast Track Designation from the FDA for retinitis pigmentosa. With no approved treatments currently available for most RP patients, this milestone could help speed the development of a promising new therapy.
Hope for RP and Stargardt Disease
Nanoscope Therapeutics is advancing a one-time gene therapy designed to restore vision for patients with retinitis pigmentosa and Stargardt disease. If successful, this treatment could transform care for two conditions that currently have no approved therapies.
Stem Cell–Derived Retinal Sheets Trial for RP
A new clinical trial is testing DSP-3077, a one-time stem cell–derived retinal sheet implant, as a potential treatment for retinitis pigmentosa. This regenerative therapy could offer hope for patients regardless of genetic subtype. Learn how this groundbreaking study may shape the future of RP treatment.